Decision-making under risk: from drugs to dopamine

How can you tell if a decision was impulsive or risky? Using the Cambridge Gambling Task to unpick how different brain regions, different drugs and different dopamine levels impact on decision-making.

The Cambridge Gambling Task (CGT) was designed to measure decision-making under risk. The term decision-making under risk refers to when the outcome of a decision is unknown, but the probability of such an outcome is known (Camerer & Weber, 1992).

The odds of winning or losing are made explicit in the CGT by the ratio of red to blue boxes. The task requires participants to decide whether a token will be hidden behind a red box or a blue box. Participants are then asked to bet a proportion of their points to support this decision.

The CGT separates itself from more traditional gambling tasks with the crucial ability to dissociate risk-taking from impulsivity. This is due to the different bet conditions of the task. In the ascending condition, the bet value incrementally increases on screen so the participant is required to wait (not be impulsive) in order to place a high-stakes bet (take a risk).

Furthermore, the task places limited demands on learning and working memory, as information from one trial does not inform the next. Consequently, the CGT is a clean measure of decision-making under risk, and therefore a good paradigm to explore the neuroscience behind such decision-making. Here we will discuss some key research into this area that has used CGT.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Cambridge Cognition Holdings

More articles like this

Cambridge Cognition Holdings

Cambridge Cognition forms new Scientific Advisory Board

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, is pleased to announce the formation of a Scientific Advisory Board. This expert board will provide scientific guidance and valuable market insights, primarily focusing

Cambridge Cognition Holdings

Cambridge Cognition Holdings Changes its Auditor to Crowe UK LL

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the Board has approved the appointment of Crowe UK LLP as the Group’s new external auditor following a competitive

Cambridge Cognition Holdings

Cambridge Cognition strengthens balance sheet with £3 million loan

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the Company has obtained a £3.0 million loan from Claret European Specialty Lending Company III, S.à r.l.  Claret specialises in

Cambridge Cognition Holdings

Cambridge Cognition Holdings Revision to Explanatory Note

Cambridge Cognition (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the explanatory note to Resolution 7 in the Notice of the Annual General Meeting (“AGM”) to be held on 28 June 2023

Cambridge Cognition Holdings

Cambridge Cognition publishes Annual Report and Accounts

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has confirmed that the Annual Report and Accounts for the year ended 31 December 2022 and the Notice of the Annual General

Cambridge Cognition Holdings

Cambridge Cognition growth strategy clearly paying off (VIDEO)

Cambridge Cognition Holdings plc (LON:COG) CEO Matthew Stork joins DirectorsTalk Interviews to discuss prelim results for the year ended 31 December 2022. In this interview Matthew talks us through the result highlights, explains how the the acquisitions